Covex S.A. creates 2000 jobs with the onset of a new agroindustrial project in Latin America
- Details
- Category: Business
Covex S.A., leader in the manufacture of products aimed at improving cerebral functions, successfully reaches the first stage of its introduction in Latin America, as it begins to harvest medicinal plants on an industrial scale, for the onset of its new agroindustrial expansion.
Bayer receives approval for its new oral contraceptive in the U.S.
- Details
- Category: Bayer
Bayer Schering Pharma AG, Germany, has received approval from The U.S. entity of Food and Drug Administration (FDA) for its new Natazia® (estradiol valerate/ dienogest) pill for the prevention of pregnancy.
RA.com Features Interactive Resource to Help People Living with Rheumatoid Arthritis
- Details
- Category: Abbott
As any do-it-yourselfer knows, a good home improvement project has both style and substance, adding functionality with aesthetic appeal. For people with rheumatoid arthritis (RA) who may face difficulties around the house, adaptable options around the home are particularly important.
New study results on Dulcolax® confirm efficacy and safety
- Details
- Category: Boehringer Ingelheim
In a clinical study Boehringer Ingelheim recently conducted, Dulcolax® tablets with the active ingredient bisacodyl clearly demonstrated efficacy by increasing the frequency and regularity of bowel movements.
GSK extends presence in Asia with new strategic alliance in South Korea
- Details
- Category: GlaxoSmithKline
GlaxoSmithKline (GSK) entered into a strategic alliance with Dong-A Pharmaceuticals Co., Ltd. (Dong-A), the number one pharmaceutical and OTC Company in South Korea.
Merck Positioned to Drive Growth Through Innovative Portfolio, Pipeline and Strategy
- Details
- Category: Merck
Merck & Co., Inc. (NYSE: MRK) hosted its first R&D and Business Briefing since completion of the Merck and Schering-Plough merger and outlined the company's strategy to drive global business growth.
Abbott licenses 24 Zydus pharmaceutical products for 15 high-growth emerging markets
- Details
- Category: Abbott
Further strengthening its global competitive position, Abbott (NYSE: ABT) announced a licensing and supply agreement with Zydus Cadila of India for a portfolio of pharmaceutical products that Abbott will commercialize in 15 emerging markets, enabling the company to further accelerate its emerging markets growth.
More Pharma News ...
- GSK Statement on FDA Advisory Committee meeting on Rotavirus vaccines
- EDUCARE (EDUcation for Cancer in African REgions) Project
- Bayer Schering Pharma Initiates Phase III Trial of Regorafenib
- Bayer Schering Pharma Initiates Phase III Trial of Regorafenib (BAY 73-4506)
- Lundbeck delivers strong growth
- Boehringer Ingelheim and Micromet announce global collaboration for multiple myeloma BiTE antibody
- Bayer Schering Pharma and EndoCeutics Enter into a Global Agreement